Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 105

1.

Hepatitis B Stigma and Knowledge among Vietnamese in Ho Chi Minh City and Chicago.

Dam L, Cheng A, Tran P, Wong SS, Hershow R, Cotler S, Cotler SJ.

Can J Gastroenterol Hepatol. 2016;2016:1910292. doi: 10.1155/2016/1910292.

2.

The time and cost investment required to obtain and initiate direct-acting antiviral therapy.

Loy V, Benyashvili T, Adams W, Pavkov D, O'Mahoney M, Cotler SJ.

Antivir Ther. 2016;21(8):731-733. doi: 10.3851/IMP3068.

PMID:
27414001
3.

Hepatitis C virus cures after direct acting antiviral-related drug-induced liver injury: Case report.

Hasin Y, Shteingart S, Dahari H, Gafanovich I, Floru S, Braun M, Shlomai A, Verstandig A, Dery I, Uprichard SL, Cotler SJ, Lurie Y.

World J Hepatol. 2016 Jul 18;8(20):858-62. doi: 10.4254/wjh.v8.i20.858.

4.

Resurrection of response-guided therapy for sofosbuvir combination therapies.

Dahari H, Halfon P, Cotler SJ.

J Hepatol. 2016 Sep;65(3):462-4. doi: 10.1016/j.jhep.2016.05.028. No abstract available.

PMID:
27242315
5.

An assessment of racial differences in the upper limits of normal ALT levels in children and the effect of obesity on elevated values.

Kliethermes S, Ma M, Purtell C, Balasubramanian N, Gonzalez B, Layden TJ, Cotler SJ.

Pediatr Obes. 2016 May 30. doi: 10.1111/ijpo.12152. [Epub ahead of print]

PMID:
27237782
6.

FAK Kinase Activity Is Required for the Progression of c-MET/β-Catenin-Driven Hepataocellular Carcinoma.

Shang N, Arteaga M, Zaidi A, Cotler SJ, Breslin P, Ding X, Kuo P, Nishimura M, Zhang J, Qiu W.

Gene Expr. 2016;17(1):79-88. doi: 10.3727/105221616X691604.

7.

Inhibition of SIRT2 suppresses hepatic fibrosis.

Arteaga M, Shang N, Ding X, Yong S, Cotler SJ, Denning MF, Shimamura T, Breslin P, Lüscher B, Qiu W.

Am J Physiol Gastrointest Liver Physiol. 2016 Jun 1;310(11):G1155-68. doi: 10.1152/ajpgi.00271.2015.

PMID:
27125275
8.

Retinoid and carotenoid status in serum and liver among patients at high-risk for liver cancer.

Kataria Y, Deaton RJ, Enk E, Jin M, Petrauskaite M, Dong L, Goldenberg JR, Cotler SJ, Jensen DM, van Breemen RB, Gann PH.

BMC Gastroenterol. 2016 Feb 29;16:30. doi: 10.1186/s12876-016-0432-5.

9.

HCV kinetic and modeling analyses indicate similar time to cure among sofosbuvir combination regimens with daclatasvir, simeprevir or ledipasvir.

Dahari H, Canini L, Graw F, Uprichard SL, Araújo ES, Penaranda G, Coquet E, Chiche L, Riso A, Renou C, Bourliere M, Cotler SJ, Halfon P.

J Hepatol. 2016 Jun;64(6):1232-9. doi: 10.1016/j.jhep.2016.02.022.

PMID:
26907973
10.

Cure prevents more than transmission of hepatitis C virus.

Dahari H, Cotler SJ, Feld JJ.

Hepatology. 2016 Sep;64(3):1003-4. doi: 10.1002/hep.28449. No abstract available.

PMID:
26755167
11.

Protease inhibitors partially overcome the interferon nonresponse phenotype in patients with chronic hepatitis C.

Duarte-Rojo A, Fischer SE, Adeyi O, Zita D, Deneke MG, Selzner N, Chen L, Malespin M, Cotler SJ, McGilvray ID, Feld JJ.

J Viral Hepat. 2016 May;23(5):340-7. doi: 10.1111/jvh.12494.

PMID:
26710754
12.

Mathematical Modeling of Hepatitis C Prevalence Reduction with Antiviral Treatment Scale-Up in Persons Who Inject Drugs in Metropolitan Chicago.

Echevarria D, Gutfraind A, Boodram B, Major M, Del Valle S, Cotler SJ, Dahari H.

PLoS One. 2015 Aug 21;10(8):e0135901. doi: 10.1371/journal.pone.0135901.

13.

Oral prenylation inhibition with lonafarnib in chronic hepatitis D infection: a proof-of-concept randomised, double-blind, placebo-controlled phase 2A trial.

Koh C, Canini L, Dahari H, Zhao X, Uprichard SL, Haynes-Williams V, Winters MA, Subramanya G, Cooper SL, Pinto P, Wolff EF, Bishop R, Ai Thanda Han M, Cotler SJ, Kleiner DE, Keskin O, Idilman R, Yurdaydin C, Glenn JS, Heller T.

Lancet Infect Dis. 2015 Oct;15(10):1167-74. doi: 10.1016/S1473-3099(15)00074-2.

14.

Sustained virological response with intravenous silibinin: individualized IFN-free therapy via real-time modelling of HCV kinetics.

Dahari H, Shteingart S, Gafanovich I, Cotler SJ, D'Amato M, Pohl RT, Weiss G, Ashkenazi YJ, Tichler T, Goldin E, Lurie Y.

Liver Int. 2015 Feb;35(2):289-94. doi: 10.1111/liv.12692.

15.

Prevalence of suspected nonalcoholic fatty liver disease in Hispanic/Latino individuals differs by heritage.

Kallwitz ER, Daviglus ML, Allison MA, Emory KT, Zhao L, Kuniholm MH, Chen J, Gouskova N, Pirzada A, Talavera GA, Youngblood ME, Cotler SJ.

Clin Gastroenterol Hepatol. 2015 Mar;13(3):569-76. doi: 10.1016/j.cgh.2014.08.037.

16.

FAK is required for c-Met/β-catenin-driven hepatocarcinogenesis.

Shang N, Arteaga M, Zaidi A, Stauffer J, Cotler SJ, Zeleznik-Le NJ, Zhang J, Qiu W.

Hepatology. 2015 Jan;61(1):214-26. doi: 10.1002/hep.27402.

17.

Understanding early serum hepatitis D virus and hepatitis B surface antigen kinetics during pegylated interferon-alpha therapy via mathematical modeling.

Guedj J, Rotman Y, Cotler SJ, Koh C, Schmid P, Albrecht J, Haynes-Williams V, Liang TJ, Hoofnagle JH, Heller T, Dahari H.

Hepatology. 2014 Dec;60(6):1902-10. doi: 10.1002/hep.27357.

18.

Presurgical transarterial chemoembolization does not increase biliary stricture incidence in orthotopic liver transplant patients.

Casadaban L, Malespin M, Cheung A, McGuffey RA, Boulay BR, Halline AG, Brown RD, Cotler SJ, Jeon H, Bui JT, Gaba RC.

Transplant Proc. 2014 Jun;46(5):1413-9. doi: 10.1016/j.transproceed.2014.03.012.

PMID:
24935306
19.

Severity of liver disease affects HCV kinetics in patients treated with intravenous silibinin monotherapy.

Canini L, DebRoy S, Mariño Z, Conway JM, Crespo G, Navasa M, D'Amato M, Ferenci P, Cotler SJ, Forns X, Perelson AS, Dahari H.

Antivir Ther. 2015;20(2):149-55. doi: 10.3851/IMP2806.

20.

Association of genetic variants with rapid fibrosis: progression after liver transplantation for hepatitis C.

Layden JE, Tayo BO, Cotler SJ, Clark NM, Baraoidan K, Friedman SL, Cooper RS.

Transplantation. 2014 May 27;97(10):1072-8. doi: 10.1097/01.TP.0000440953.06886.a3.

Items per page

Supplemental Content

Loading ...
Support Center